Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lachlan R Gray

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Viruses|July 2, 2021
Modular Lentiviral Vectors for Highly Efficient Transgene Expression in Resting Immune CellsChristina Fichter, Anupriya Aggarwal, Andrew Kam Ho Wong, et al.
Journal of Leukocyte Biology|October 19, 2012
Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5Hamid Salimi, Michael Roche, Nicholas Webb, et al.
Plos One|March 4, 2014
HIV-1 entry and trans-infection of astrocytes involves CD81 vesiclesLachlan R Gray, Stuart G Turville, Tina L Hitchen, et al.
Plos One|November 20, 2014
Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapyHao K Lu, Lachlan R Gray, Fiona Wightman, et al.
Plos One|April 25, 2013
The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytesLachlan R Gray, Gilda Tachedjian, Anne M Ellett, et al.
Virology|June 24, 2010
An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopesJasminka Sterjovski, Michael Roche, Melissa J Churchill, et al.
Scientific Reports|February 26, 2015
Reliable genotypic tropism tests for the major HIV-1 subtypesKieran Cashin, Lachlan R Gray, Katherine L Harvey, et al.
AIDS Research and Human Retroviruses|August 12, 2017
Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 AntagonistsJacqueline K Flynn, Paula Ellenberg, Renee Duncan, et al.
Virology|April 23, 2013
The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsetsJacqueline K Flynn, Geza Paukovics, Miranda S Moore, et al.
Retrovirology|December 14, 2007
Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDSJasminka Sterjovski, Melissa J Churchill, Anne Ellett, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Viruses|July 2, 2021
Modular Lentiviral Vectors for Highly Efficient Transgene Expression in Resting Immune CellsChristina Fichter, Anupriya Aggarwal, Andrew Kam Ho Wong, et al.
Journal of Leukocyte Biology|October 19, 2012
Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5Hamid Salimi, Michael Roche, Nicholas Webb, et al.
Plos One|March 4, 2014
HIV-1 entry and trans-infection of astrocytes involves CD81 vesiclesLachlan R Gray, Stuart G Turville, Tina L Hitchen, et al.
Plos One|November 20, 2014
Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapyHao K Lu, Lachlan R Gray, Fiona Wightman, et al.
Plos One|April 25, 2013
The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytesLachlan R Gray, Gilda Tachedjian, Anne M Ellett, et al.
Virology|June 24, 2010
An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopesJasminka Sterjovski, Michael Roche, Melissa J Churchill, et al.
Scientific Reports|February 26, 2015
Reliable genotypic tropism tests for the major HIV-1 subtypesKieran Cashin, Lachlan R Gray, Katherine L Harvey, et al.
AIDS Research and Human Retroviruses|August 12, 2017
Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 AntagonistsJacqueline K Flynn, Paula Ellenberg, Renee Duncan, et al.
Virology|April 23, 2013
The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsetsJacqueline K Flynn, Geza Paukovics, Miranda S Moore, et al.
Retrovirology|December 14, 2007
Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDSJasminka Sterjovski, Melissa J Churchill, Anne Ellett, et al.
Pageof 3